- Agennix shutters Houston site
- Hopp not wavering but sinking €80m into CureVac
- Investors cool on new bavi data in NSCLC but Peregrine eyes Phase III
- Celgene solid in 3Q, looks to Abraxane's potential in melanoma
ONLY 0 DAY LEFT
|Stay close to your market. Renew online now to ensure uninterrupted access to:|
|SCRIP Intelligence's news and expert commentary|
|Market Data and Company Analysis (SCRIP 100, SCRIP Asia 100)|
|The Ask the Analyst Service...and more.|
Please remember to quote your order number and customer number.
You can also renew by calling: +44 (0)20 7017 5540.